The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 718-721

  Mann, Nirmal S ^a,b   Limoges Gonzales, Michele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCDMC Folsom Campus ^*  (United States)

Author keywords

Bacterial overgrowth; Irritable bowel syndrome; Prevalence; Small intestine

Indexed keywords

LACTULOSE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL GROWTH; CONSTIPATION; CONTROLLED STUDY; FEMALE; HUMAN; HYDROGEN BREATH TEST; INTESTINE FLORA; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLIND LOOP SYNDROME; BREATH TESTS; COHORT STUDIES; CONSTIPATION; DIARRHEA; FEMALE; HUMANS; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67651216399     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Drossman DA, Funch-Jensen P, Janssens J, Talley NJ, Thomposn WG, Whitehead WE: Identification of Sub-groups of functional bowel disorders. Gastroenterology Int 1990; 3:159-172.
2. Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of function bowel disorders. BMJ 1978; 2:653-654. (Pubitemid 9004104)
3. Thompson WG, Creed FH, Drossman DA, Heaton KW, Mazzacca G: Functional bowel disorders and functional abdominal pain. Gastroenterology Int 1992; 5:75-91.
4. Thompson WG, Irvine EJ, Pare P, Ferrazi S, Rance L: Functional gastrointestinal disorders in Canada: first population - based survey using the Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47:225-235. (Pubitemid 34075042)
5. Thompson WG: Rome I vs Rome II. Gastroenterol Int 2000; 13:159-162.
6. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterolgoy 2006; 130:1377-1390.
7. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Fermin M, Spiller RC: Functional bowel disorders. Gastroentrology 2006; 130:1480-1491.
8. Gwee KA: Irritable bowel syndrome in developing countries: a disorder of civilization or colonization? Neurogastrenterol Motil 2005; 17:317-324.
9. Sait YA, Schoenfield P, Locke GRI: The epidemiology of irritable bowel syndrome in North America: a systematic review Am J Gastroenteral 2002; 97:1910-1915.
10. Longstreth GF: Definition and classification of IBS: current consensus and controversies. Gastroenteral Clin North Am 2005; 34:173-187. (Pubitemid 40615949)
11. Wilson A, Longstreth G, Knight K, Wong J, Wade S, Chiou C, Barghout V, Freeh F, Ofman J: Quality of life in managed care patients with irritable bowel syndrome. Manage Care Interface 2004; 17:24-28. (Pubitemid 38209388)
12. Whitehead WE, Palsson O, Jones KR: Systematic review of the co morbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterolgoy 2002; 122:1140-1156. (Pubitemid 34267295)
13. Longstreth GF, Wilson A, Knight K Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ: Irritable bowel syndrome, health care use and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98:600-607. (Pubitemid 36348532)
14. Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterolgy 2002; 123:2108-2131. (Pubitemid 35408332)
15. Harris LA, Crowell MD, DiBaise JK, Olden K: Is small intestinal bacterial overgrowth really prevalent in irritable bowel syndrome? Am J Gastroenterol 2005; 100:5336-5337. (Abstract)
16. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-3506.
17. Mann NS, Shinkle JM: Effect of Clonidine on gastrointestinal transit time. Hepato-Gastroenterology 1998; 45:1023-1025. (Pubitemid 28403286)
18. Colton T: Statistics in Medicine. Boston: Little, Brown and Co. 1974; pp. 174-180.
19. Ruff KC, Saito-Loftus YA, Locke GR, Harmsen WS, Zinmeister AS, Talley NJ: Failure to detect association with irritable bowel syndrome and small intestinal bacterial overgrowth. Am J Gastroenterol 2006; 101:S488. (Abstract)
20. Pimentel M, Chatterjee S, Chang C, Low K, Song Y, Liu C, Lezcano S, Conklin J, Finegold S: Gastrointestinal infection with Campylobacter jejuni 81-176 produces altered bowel function and bacterial overgrowth in rats. Am J Gastroenterol 2006; 101:S472 (Abstract).
21. Hyo-Rang L, Low K, Chatterjee S, Yang J, Conklin J, Pimentel M: In the treatment of IBS, the clinical response to Rifaximin is determined by the normalization of the lactulose breath test. Am J Gastroenterol 2006; 101:S474. (Abstract)
22. Hyo-Rang L, Low K, Chatterjee S, Yang J, Conklin J, Pimentel M: Rifaximin is superior to other antibiotics in treating and retreating bacterial overgrowth in IBS, supporting a lack of bacterial resistance development. Am J Gastroenterol 2006; 101:S475. (Abstract)